{"hands_on_practices": [{"introduction": "A cornerstone of modern cell biology is the ability to dissect complex cellular processes using specific molecular tools. This first practice problem challenges you to think like a researcher by matching key small molecule inhibitors to the distinct cell death pathways they target [@problem_id:2326183]. By understanding how these inhibitors work, you can begin to design experiments that distinguish between necroptosis, pyroptosis, and ferroptosis based on their unique molecular machinery.", "problem": "A cell biology researcher is investigating three distinct forms of regulated cell death: necroptosis, a programmed necrosis dependent on Receptor-Interacting Protein Kinase 1 (RIPK1) and RIPK3; pyroptosis, an inflammatory cell death driven by the activation of inflammatory caspases like Caspase-1; and ferroptosis, a non-apoptotic death process characterized by iron-dependent lipid peroxidation. To dissect these pathways experimentally, the researcher uses a panel of specific small molecule inhibitors. The available inhibitors are:\n\n1.  **Necrostatin-1**: A well-characterized allosteric inhibitor of a key kinase.\n2.  **VX-765**: A potent and selective inhibitor of Caspase-1.\n3.  **Ferrostatin-1**: A radical-trapping antioxidant.\n\nYour task is to correctly match each inhibitor to the single cell death pathway it is designed to block. Which of the following options represents the correct set of pairings?\n\nA.\nNecrostatin-1 → Pyroptosis\nVX-765 → Ferroptosis\nFerrostatin-1 → Necroptosis\n\nB.\nNecrostatin-1 → Ferroptosis\nVX-765 → Necroptosis\nFerrostatin-1 → Pyroptosis\n\nC.\nNecrostatin-1 → Necroptosis\nVX-765 → Pyroptosis\nFerrostatin-1 → Ferroptosis\n\nD.\nNecrostatin-1 → Pyroptosis\nVX-765 → Necroptosis\nFerrostatin-1 → Ferroptosis\n\nE.\nNecrostatin-1 → Necroptosis\nVX-765 → Ferroptosis\nFerrostatin-1 → Pyroptosis", "solution": "We identify the molecular targets and mechanisms for each inhibitor and match them to the defining drivers of each regulated cell death pathway:\n\n1. Necroptosis is a programmed form of necrosis dependent on the kinase activity of RIPK1 and RIPK3. Necrostatin-1 is a well-characterized allosteric inhibitor of RIPK1. Therefore, inhibiting RIPK1 with Necrostatin-1 blocks necroptosis.\n\n2. Pyroptosis is an inflammatory cell death driven by inflammatory caspases, particularly Caspase-1, which processes gasdermin D to execute membrane pore formation. VX-765 is a potent and selective inhibitor of Caspase-1. Therefore, inhibiting Caspase-1 with VX-765 blocks pyroptosis.\n\n3. Ferroptosis is a non-apoptotic cell death characterized by iron-dependent lipid peroxidation. Ferrostatin-1 is a radical-trapping antioxidant that prevents lipid peroxidation chain reactions. Therefore, Ferrostatin-1 blocks ferroptosis.\n\nComparing these mappings to the options, the correct set is:\nNecrostatin-1 → Necroptosis; VX-765 → Pyroptosis; Ferrostatin-1 → Ferroptosis, which corresponds to option C.", "answer": "$$\\boxed{C}$$", "id": "2326183"}, {"introduction": "Cellular signaling pathways are rarely linear; they are interconnected networks that allow cells to adapt to different challenges. This next exercise explores the critical concept of pathway crosstalk, focusing on the well-established switch between apoptosis and necroptosis [@problem_id:2326191]. By predicting the outcome of blocking key signaling nodes, you will gain a deeper appreciation for how inhibiting one death pathway can reveal the activity of another.", "problem": "A cell biology research team is investigating regulated cell death pathways in a specialized line of human intestinal epithelial cells. These cells possess the complete molecular machinery to undergo either apoptosis or necroptosis in response to specific stimuli. The team uses Tumor Necrosis Factor-$\\alpha$ (TNF-$\\alpha$) as the primary stimulus to induce cell death.\n\nIn an initial experiment, treating the cells with TNF-$\\alpha$ alone results in widespread cell death. In a second experiment, the team co-treats the cells with TNF-$\\alpha$ and a potent pan-caspase inhibitor (a molecule that blocks the activity of all caspase enzymes). They observe that this co-treatment does not prevent cell death, indicating that a non-apoptotic death pathway is activated.\n\nBuilding on this, the team prepares two new experimental conditions. For both conditions, the epithelial cells are first treated with the combination of TNF-$\\alpha$ and the pan-caspase inhibitor. Then, a second inhibitor is added:\n\n*   **Condition A:** A highly specific inhibitor of the kinase activity of Receptor-Interacting Protein Kinase 1 (RIPK1) is added to the culture.\n*   **Condition B:** A potent and specific inhibitor of the pseudokinase Mixed Lineage Kinase domain-Like protein (MLKL) is added to the culture.\n\nBased on your understanding of the canonical signaling pathways that govern apoptosis and necroptosis, predict the most likely outcomes for the cell populations in Condition A and Condition B.\n\nA. Condition A: Widespread cell death; Condition B: Widespread cell death.\n\nB. Condition A: Cell survival; Condition B: Widespread cell death.\n\nC. Condition A: Widespread cell death; Condition B: Cell survival.\n\nD. Condition A: Cell survival; Condition B: Cell survival.\n\nE. Condition A: Cells switch to ferroptosis; Condition B: Cells switch to pyroptosis.", "solution": "- TNF-$\\alpha$ engages TNFR1 and forms membrane complex I (including TRADD, TRAF2, cIAPs, RIPK1), which can promote pro-survival NF-$\\kappa$B signaling. Under conditions favoring death complex formation, RIPK1 dissociates and assembles cytosolic complex II with FADD and caspase-8, initiating extrinsic apoptosis via caspase activation.\n\n- Initial experiment: TNF-$\\alpha$ alone causes widespread death. In cells with intact apoptotic machinery, TNF-$\\alpha$ commonly induces apoptosis via caspase-8 activation; thus the observed death is consistent with apoptosis as the predominant mode.\n\n- Second experiment: TNF-$\\alpha$ plus a pan-caspase inhibitor still results in death. Inhibition of caspases (notably caspase-8) blocks apoptosis and lifts the caspase-8–mediated suppression of the necroptosis pathway (caspase-8 normally cleaves and inactivates RIPK1/RIPK3). With caspases inhibited, TNF-$\\alpha$ signaling can proceed via the canonical necroptosis axis: RIPK1 kinase activity promotes assembly of the necrosome with RIPK3, leading to RIPK3-mediated phosphorylation and activation of MLKL, MLKL oligomerization and translocation to membranes, and execution of necroptotic lytic death. Therefore, the persistence of death under caspase inhibition indicates activation of necroptosis.\n\n- Condition A: Add a highly specific RIPK1 kinase inhibitor on top of TNF-$\\alpha$ plus pan-caspase inhibitor.\n  - Canonical requirement: Necroptosis depends on RIPK1 kinase activity (for TNF-$\\alpha$-driven necrosome assembly and signal propagation to RIPK3).\n  - Effect of inhibition: Blocking RIPK1 kinase activity prevents necrosome formation and downstream RIPK3/MLKL activation, thereby aborting necroptosis.\n  - With apoptosis already blocked by the pan-caspase inhibitor and necroptosis blocked by the RIPK1 kinase inhibitor, no major regulated death pathway remains engaged by TNF-$\\alpha$ in this canonical context; thus the most likely outcome is cell survival.\n\n- Condition B: Add a potent and specific MLKL inhibitor on top of TNF-$\\alpha$ plus pan-caspase inhibitor.\n  - Canonical requirement: MLKL is the terminal effector of necroptosis; its activation and oligomerization are required for membrane permeabilization and cell lysis.\n  - Effect of inhibition: Blocking MLKL prevents execution of necroptosis downstream of RIPK1/RIPK3, even if the upstream necrosome forms.\n  - With apoptosis blocked (pan-caspase inhibitor) and necroptosis execution blocked (MLKL inhibitor), cells are expected to survive under canonical signaling.\n\n- Conclusion:\n  - Condition A: Cell survival (necroptosis blocked at RIPK1; apoptosis blocked by pan-caspase inhibitor).\n  - Condition B: Cell survival (necroptosis blocked at MLKL; apoptosis blocked by pan-caspase inhibitor).\n\nTherefore, the correct choice is D.", "answer": "$$\\boxed{D}$$", "id": "2326191"}, {"introduction": "To truly understand a pathway, we must dissect the specific roles of its individual components. This final practice problem uses a hypothetical genetic knockout to probe the inner workings of pyroptosis [@problem_id:2326185]. You will analyze the consequences of losing the key executioner protein, Gasdermin D, to understand how this pathway distinctly regulates both cell lysis and the release of inflammatory signals.", "problem": "Pyroptosis is a highly inflammatory form of programmed cell death crucial for host defense against intracellular pathogens. This process is typically initiated by the assembly of a cytosolic protein complex called the inflammasome in response to pathogen-associated or danger-associated molecular patterns. The activated inflammasome, in turn, activates the enzyme Caspase-1. Active Caspase-1 then carries out two primary functions: it cleaves pro-inflammatory cytokines, such as pro-Interleukin-1β (pro-IL-1β), into their biologically active forms, and it cleaves a protein called Gasdermin D (GSDMD). The N-terminal fragment of cleaved GSDMD oligomerizes and inserts into the plasma membrane, forming large pores that lead to cell swelling, lysis, and the release of the mature cytokines.\n\nConsider a macrophage isolated from a genetically engineered mouse that completely lacks a functional gene for Gasdermin D. This macrophage is then infected by a species of intracellular bacteria that is known to robustly trigger inflammasome activation. Which of the following statements most accurately describes the expected cellular and inflammatory outcome in this GSDMD-deficient macrophage compared to a wild-type macrophage under the same conditions?\n\nA. The cell will undergo an alternative form of programmed cell death, apoptosis, which will efficiently release the mature IL-1β.\n\nB. The inflammasome will fail to assemble because GSDMD is a required upstream component, preventing any cellular response.\n\nC. The cell will still undergo pyroptotic lysis, but it will be unable to produce mature IL-1β.\n\nD. The cell will successfully produce mature IL-1β, but it will fail to undergo pyroptosis and will not efficiently release the cytokine into the extracellular space.\n\nE. The cell will remain viable and unharmed, secreting mature IL-1β through specialized exocytosis machinery that compensates for the lack of GSDMD.", "solution": "The problem asks us to predict the consequences of a Gasdermin D (GSDMD) deficiency in a macrophage during a bacterial infection that triggers the inflammasome pathway. To solve this, we must analyze the sequence of events in pyroptosis and identify which steps are dependent on GSDMD.\n\nStep 1: The Canonical Pyroptosis Pathway.\nIn a normal (wild-type) macrophage, the process unfolds as follows:\n1.  An intracellular bacterium provides signals that lead to the assembly of the inflammasome complex.\n2.  The assembled inflammasome recruits and activates pro-Caspase-1 into its active form, Caspase-1.\n3.  Active Caspase-1 acts on its substrates.\n    a.  It cleaves pro-Interleukin-1β (pro-IL-1β), which is inactive, into mature, active IL-1β, a potent pro-inflammatory cytokine.\n    b.  It cleaves Gasdermin D (GSDMD) into an N-terminal fragment (GSDMD-N) and a C-terminal fragment (GSDMD-C).\n\n4.  The GSDMD-N fragment translocates to the inner leaflet of the plasma membrane.\n5.  Multiple GSDMD-N fragments insert into the membrane and oligomerize to form large pores, approximately 10-20 nm in diameter.\n6.  These pores disrupt the cell's osmotic balance, leading to water influx, cell swelling (oncosis), and eventual rupture (lysis). This lytic death is called pyroptosis.\n7.  The pores also serve as conduits for the passive release of cytosolic contents, including the mature IL-1β and other inflammatory molecules, into the extracellular environment, thereby propagating a strong inflammatory response.\n\nStep 2: Analysis of the GSDMD-deficient Macrophage.\nNow, let's consider the scenario where the macrophage lacks a functional GSDMD gene. We will trace the pathway again.\n1.  The bacterial infection still provides the necessary signals. GSDMD is not involved in the initial sensing or assembly of the inflammasome. Therefore, the inflammasome will assemble correctly.\n2.  The assembled inflammasome will successfully activate Caspase-1.\n3.  Active Caspase-1 will search for its substrates.\n    a.  Pro-IL-1β is present in the cell, so Caspase-1 will cleave it into mature, active IL-1β. This mature cytokine will accumulate in the cytosol of the macrophage.\n    b.  Caspase-1 attempts to cleave GSDMD, but the protein is absent due to the gene knockout. This step fails.\n\n4.  Since GSDMD is not cleaved, the pore-forming GSDMD-N fragment is never generated.\n5.  Without the GSDMD-N fragment, no pores are formed in the plasma membrane.\n6.  Without the pores, the cell does not undergo the characteristic swelling and lytic death of pyroptosis.\n7.  Without the pores, the mature IL-1β that has accumulated in the cytosol has no efficient pathway for release. The cell effectively traps the potent inflammatory signal it has produced. The overall inflammatory response initiated by this specific cell is therefore severely diminished. The cell may eventually die via other, slower pathways like apoptosis, but the rapid, inflammatory burst of pyroptosis is prevented.\n\nStep 3: Evaluation of the Multiple-Choice Options.\nBased on the analysis above, we can evaluate each option:\n\nA. The cell will undergo an alternative form of programmed cell death, apoptosis, which will efficiently release the mature IL-1β.\nThis is incorrect. While the cell might eventually die by apoptosis, apoptosis is characterized by the formation of contained apoptotic bodies and is generally considered non-inflammatory. It does not provide an efficient mechanism for the release of soluble cytosolic proteins like IL-1β.\n\nB. The inflammasome will fail to assemble because GSDMD is a required upstream component, preventing any cellular response.\nThis is incorrect. GSDMD is a downstream effector of Caspase-1. Inflammasome assembly and Caspase-1 activation occur upstream of and are independent of GSDMD.\n\nC. The cell will still undergo pyroptotic lysis, but it will be unable to produce mature IL-1β.\nThis is incorrect. It reverses the actual outcome. The cell is unable to undergo pyroptotic lysis because it lacks the pore-forming protein (GSDMD). However, it is fully capable of producing mature IL-1β because the upstream machinery (inflammasome and Caspase-1) is functional.\n\nD. The cell will successfully produce mature IL-1β, but it will fail to undergo pyroptosis and will not efficiently release the cytokine into the extracellular space.\nThis is correct. As determined in our analysis, Caspase-1 activation leads to the cleavage of pro-IL-1β, but the absence of GSDMD prevents pore formation, cell lysis (pyroptosis), and subsequent cytokine release.\n\nE. The cell will remain viable and unharmed, secreting mature IL-1β through specialized exocytosis machinery that compensates for the lack of GSDMD.\nThis is incorrect. The cell is under significant stress from the infection and the active Caspase-1; it will not remain \"viable and unharmed\" indefinitely. Furthermore, while some unconventional secretion mechanisms for IL-1β exist, they are not the primary pathway in this context and cannot fully compensate for the massive, rapid release mediated by GSDMD pores. The defining feature of this knockout is the *failure* to release the cytokine efficiently.", "answer": "$$\\boxed{D}$$", "id": "2326185"}]}